Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Dr. Reddy’s Laboratories Limited is scheduled to consider its financial results for the third quarter of FY25–26 at a meeting of the Board of Directors on Wednesday, 21 January 2026. The results will be disclosed through filings submitted to the stock exchanges as part of the regular quarterly reporting process.
Dr. Reddy’s Laboratories Limited is an Indian pharmaceutical company with operations spanning generic medicines, active pharmaceutical ingredients, and specialty products. The company’s equity shares are listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
The previous reported quarter ended on 30 September 2025. During this period, Dr. Reddy’s Laboratories Limited reported revenue of ₹8,828 crore. Operating profit for the quarter stood at ₹2,010 crore, with an operating margin of 23%. Profit before tax (PBT) was reported at ₹1,745 crore, while profit after tax (PAT) stood at ₹1,337 crore. Earnings per share (EPS) for the quarter were ₹16.14. All figures mentioned here are taken from the company’s disclosed financials and official stock exchange filings.
During the trading session on 7 January 2026, shares of Dr. Reddy’s Laboratories Limited were trading at ₹1,244.90 on the NSE. At that time, the stock was lower by ₹11.30, reflecting a decline of 0.90% for the day. The price movement was observed around 3:30 PM IST based on live market data and may change during market hours.
Quarterly results are released to formally place a company’s financial performance on record for a defined reporting period. These disclosures are made through official stock exchange filings. This page has been created to provide background information ahead of the Q3 FY25–26 results announcement and will be updated once the official filing is made available.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading